-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CStone Pharmaceuticals announced on September 15 that the clinical trial application of the multispecific antibody CS2006/NM21-1480 in China was approved by the China National Medical Products Administration
.
CS2006/NM21-1480 is a monovalent trispecific antibody targeting PD-L1, 4-1BB and human serum albumin (HSA)
.
According to its molecular design, CS2006/NM21-1480 can only conditionally induce the immune costimulatory receptor 4-1BB and activate anti-cancer T cells when combined with the immune checkpoint ligand PD-L1 on the surface of tumor cells.
Compared with other PD-L1/4-1BB bispecific candidate antibodies, CS2006/NM21-1480's unique monovalent structure design and ultra-high affinity for PD-L1 will enable the dual effects of PD-L1 and 4-1BB in the tumor.
Maximize the potential of the drug while avoiding systemic toxicity
.
In addition, the half-life can be extended by combining HSA
Note: The original text has been deleted